Veterans Day is a time to “think about how we can work together and think about ways to give back to those who have served,” said John Crowley, CEO of Amicus Therapeutics and U.S. Navy veteran last year—and today, we’re thinking in particular about women veterans and how we can address their needs.
Women are the fastest-growing veterans group—totaling 2 million today. Women comprised 4% of veterans in 2020 and are expected to reach 18% by 2040.
We need to address their immediate and long-term needs,said experts during BIO’s Patient Advocacy Coffee Chat earlier this week. The discussion featured patient advocates—all women, and many veterans—from groups including the National Military Family Association, Service Women’s Action Network, HealthyWomen, Disabled American Veterans, and Paralyzed Veterans of America.
“Communication is key,” said Julie Howell, Associate Legislative Director of Paralyzed Veterans of America (PVA), who served in the U.S. Army from 2000 to 2005, joining at 17. It’s “critical and vital” to support partnerships and ensure “everyone is talking to one another.”
Biotech can learn from veterans’ “notion of service and sacrifice,” said Crowley last year, discussing his journey from three active-duty tours to a career in biotech. “It’s what we do every day in biotechnology to support people living with disease and to extend and enhance their lives in different ways.”
The big picture: “That bigger sense of mission, of purpose, is very clear to us in the military and it’s equally clear in biotechnology,” he continued.
Read more about this week’s chat.
More Health Care News:
Bio.News Exclusive: To ensure access for all, healthcare payment models need innovation
“When government and industry partner together to understand the needs of every player, they can balance their budgets, ensure continued healthcare innovation, and ultimately make certain that patients get the access and treatment they need to live their lives well.”
Biogen: Biogen Names Christopher Viehbacher President and Chief Executive Officer
“Chris is the rare pharma executive who has a keen understanding of the complexities involved in running a multibillion-dollar global pharma business as well as a deep appreciation for the value of innovation,” said Stelios Papadopoulos, Ph.D., Chairman of the Board of Biogen.